CND Life Sciences (Series A)
Funding Details
Awarder
Inbox
Date Award
May 16, 2025
Vertical
Life Sciences
Funding URL
View Funding Page
Funding Amount
$13,500,000
Company Info
Traction
Results of a prospective, multicenter NIH-sponsored study of the Syn-One Test were published in JAMA in 2024 demonstrating >95% sensitivity overall in patients with a clinically determined synucleinopathy.
Market
Neurodegenerative diseases
Location
Scottsdale, Arizona, USA
Coinvestors
Cambrian Capital Partners, Tanis Ventures, Lupo Labs, Top Corner Capital, HonorHealth, Triana, Gold Bench Capital, BlueStone Ventures, Labcorp, MBX Capital, Vilas Ventures
Company Description

CND Life Sciences supports the care of patients facing the potential diagnosis of neurodegenerative disease and other neurological conditions. The company developed the Syn-One Test to help clinicians diagnose synucleinopathies that include Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy.

Links
Website
Back to HomeBack to Life Sciences DealsView Funding Announcement